Segui i tuoi podcast preferiti, ascolta offline e in auto con CarPlay e Android Auto, e riprendi sempre da dove eri rimasto. Provala gratis.
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. A cura di Luca Sacchetta, Ilaria Milani e Giuseppe Della Pepa
Articolo di riferimento: Nicholas A. Marston, Erin A. Bohula, Ajay K. Bhatia, et al. Investigators. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA 16, 335 (2026). https:// doi:10.1001/jama.2026.3277